Publications

Trends in molecular medicine

An Experimenter's Guide to Glioblastoma Invasion Pathways.

01-09-2018

The Journal of clinical investigation

Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

31-08-2018

Clinical cancer research : an official journal of the American Association for Cancer Research

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

15-08-2018

Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018

Frontiers of medicine

Taking advantage of drug resistance, a new approach in the war on cancer.

01-08-2018

Cell research

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

01-07-2018

Nature medicine

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

01-07-2018

Cell research

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

01-06-2018

Cell

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

31-05-2018

The EMBO journal

Anti-cancer therapy: senescence is the new black.

15-05-2018

Molecular cancer therapeutics

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

01-04-2018

Hepatology (Baltimore, Md.)

In vivo veritas: Finding novel genes involved in liver cancer through in vivo genetic screens.

01-12-2017

Annals of surgical oncology

Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.

01-12-2017

High-throughput

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

06-11-2017

Cell reports

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

17-10-2017

Breast cancer research : BCR

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

25-08-2017

Cell reports

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

05-07-2017

Breast cancer research and treatment

A breast cancer gene signature for indolent disease.

01-07-2017

European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017

Nature reviews. Clinical oncology

Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

01-06-2017

Nature communications

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

31-05-2017

The New England journal of medicine

Clinical Trials Series — Large Pharma.

06-04-2017

Cell

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

09-02-2017

Biomarker insights

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.

17-12-2016

eLife

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

15-11-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

01-11-2016

The journal of pathology. Clinical research

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.

01-10-2016

Oncogene

Targeting the RB-E2F pathway in breast cancer.

15-09-2016

The New England journal of medicine

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

25-08-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

01-08-2016

Cancer research

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

01-08-2016

Annals of oncology : official journal of the European Society for Medical Oncology

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

01-08-2016

Oncotarget

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

21-06-2016

Nature biotechnology

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

01-06-2016

Molecular cancer research : MCR

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

01-05-2016

Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016

Breast cancer research and treatment

Equivalence of MammaPrint array types in clinical trials and diagnostics.

01-04-2016

Oncogene

Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

03-03-2016

European urology

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

01-03-2016

Cancer discovery

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

01-02-2016

Oncotarget

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

19-01-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Oncotarget

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

15-12-2015

Current colorectal cancer reports

Treatment Individualization in Colorectal Cancer.

01-12-2015

Nature medicine

The consensus molecular subtypes of colorectal cancer.

01-11-2015

Breast cancer research : BCR

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

03-10-2015

Molecular oncology

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

01-10-2015

Cell reports

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

29-09-2015

European urology

Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.

01-08-2015

Cell research

A price to pay for tumor regression.

01-07-2015

An Experimenter's Guide to Glioblastoma Invasion Pathways.

Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

Taking advantage of drug resistance, a new approach in the war on cancer.

MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Anti-cancer therapy: senescence is the new black.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

In vivo veritas: Finding novel genes involved in liver cancer through in vivo genetic screens.

Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival.

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers.

High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

A breast cancer gene signature for indolent disease.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Drug therapy: Exploiting synthetic lethality to improve cancer therapy.

Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.

Clinical Trials Series — Large Pharma.

How Much Longer Will We Put Up With $100,000 Cancer Drugs?

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.

FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.

Targeting the RB-E2F pathway in breast cancer.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.

CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes.

Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma.

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Opportunities and challenges provided by crosstalk between signalling pathways in cancer.

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.

DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?

An integrated genomic approach identifies that the PI3K/AKT/FOXO pathway is involved in breast cancer tumor initiation.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor.

Treatment Individualization in Colorectal Cancer.

The consensus molecular subtypes of colorectal cancer.

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response.

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.

A price to pay for tumor regression.

This site uses cookies

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.